secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001558370-24-003704
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharma Q4 loss $9.6M; secures $35M loan at 14%, matures June 2025
------------------------------------------------------------------------

- Q4 2023 loss from operations $(9.6)M vs $(10.3)M in Q4 2022; cash $13.5M at Dec 31, 2023.
- Entered $35M credit agreement with Innoviva SO on March 4, 2024; 14% annual rate, matures June 4, 2025.
- Phase 2 diSArm study of AP-SA02 for Staph aureus bacteremia continues dose escalation; Phase 2 Tailwind study of AP-PA02 for NCFB progressing.
- Manufacturing facility advanced; R&D labs completed; five cGMP suites expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000155837024003704/0001558370-24-003704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000155837024003704/armp-20240321x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-003704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer